By MedPage Today | June 10, 2015
As expected, an FDA advisory panel recommended that Amgen's entry in the PCSK9 class, evolocumab (Repatha) should receive marketing approval.
Physicians are in short supply. They are costly. Is the APP the answer to the CMO's workforce and budget challenges? ...
Amid the hype and promise, a growing tension is becoming clear: the reality of what AI can deliver versus what it can't. ...
